Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China.
Laboratory of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, Yunnan, China.
Cell Rep. 2021 Dec 14;37(11):110112. doi: 10.1016/j.celrep.2021.110112. Epub 2021 Nov 24.
An ideal vaccine against SARS-CoV-2 is expected to elicit broad immunity to prevent viral infection and disease, with efficient viral clearance in the upper respiratory tract (URT). Here, the N protein and prefusion-full S protein (SFL) are combined with flagellin (KF) and cyclic GMP-AMP (cGAMP) to generate a candidate vaccine, and this vaccine elicits stronger systemic and mucosal humoral immunity than vaccines containing other forms of the S protein. Furthermore, the candidate vaccine administered via intranasal route can enhance local immune responses in the respiratory tract. Importantly, human ACE2 transgenic mice given the candidate vaccine are protected against lethal SARS-CoV-2 challenge, with superior protection in the URT compared with that in mice immunized with an inactivated vaccine. In summary, the developed vaccine can elicit a multifaceted immune response and induce robust viral clearance in the URT, which makes it a potential vaccine for preventing disease and infection of SARS-CoV-2.
一种理想的针对 SARS-CoV-2 的疫苗有望引发广泛的免疫反应，以预防病毒感染和疾病，并在上呼吸道 (URT) 中有效清除病毒。在这里，N 蛋白和融合前全长 S 蛋白 (SFL) 与鞭毛蛋白 (KF) 和环鸟苷酸-腺苷酸 (cGAMP) 结合，生成候选疫苗，该疫苗比包含其他形式 S 蛋白的疫苗引发更强的系统和粘膜体液免疫。此外，通过鼻内途径给予候选疫苗可增强呼吸道的局部免疫反应。重要的是，给予候选疫苗的人 ACE2 转基因小鼠可免受致死性 SARS-CoV-2 攻击，与用灭活疫苗免疫的小鼠相比，在 URT 中具有更好的保护作用。总之，所开发的疫苗可以引发多方面的免疫反应，并在上呼吸道中诱导强大的病毒清除，这使其成为预防 SARS-CoV-2 疾病和感染的潜在疫苗。
